NDSN Stock Analysis: Nordson | NASDAQ

Dispensing Systems, Coating Equipment, Medical Devices, Testing

Total Rating 78

Safety 81

Buy Signal 1.04

Specialty Industrial Machinery
Industry Rotation: +1.3

Market Cap: 18.6B
Avg Turnover: 107M

Risk 3d forecast

Volatility22.8%

VaR 5^th Pctl3.69%

VaR vs Median-1.77%

Reward TTM

Sharpe Ratio1.84

Rel. Str. IBD80.2

Rel. Str. Peer Group83.9

Character TTM

Beta1.029

Beta Downside1.118

Hurst Exponent0.460

Drawdowns 3y

Max DD39.15%

CAGR/Max DD0.33

CAGR/Mean DD1.13

EPS (Earnings per Share)

EPS CAGR: 8.06%
EPS Trend: 95.3%

Last SUE: 2.51
Qual. Beats: 1

Revenue

Rev. CAGR: 4.34%
Rev. Trend: 94.2%

Last SUE: 2.71
Qual. Beats: 1

Warnings

Extended 1w

Tailwinds

Supp Ema8

Idiosyncratic Leader

Pead

Tailwind

Seasonality 11.6 years of data

Jan -3.9% 17

Feb +0.5% 5

Mar -0.2% 17

Apr -1.8% 11

May +0.1% 7

Jun +0.7% 8

Jul +0.3% 26

Aug +0.3% 2

Sep -0.9% 17

Oct +0.1% 2

Nov +1.9% 30

Dec -0.1% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: NDSN Nordson

Nordson Corporation (NDSN) is a U.S.-based industrial machinery manufacturer that engineers, produces, and markets precision dispensing, application, and control systems for adhesives, coatings, polymers, sealants, biomaterials, and other fluids. Founded in 1909 and headquartered in Westlake, Ohio, the company is a large-cap NASDAQ-listed stock classified within the Industrials sector, specifically the Industrial Machinery & Supplies & Components sub-industry.

The business operates through three reportable segments. Industrial Precision Solutions supplies dispensing, coating, and laminating systems used in disposable products, roll goods, and container/powder coating applications. Medical and Fluid Solutions provides precision dispensers, plastic molded syringes and cartridges, medical tubing, balloons, nitinol devices, and biomaterial delivery components. Advanced Technology Solutions delivers automated dispensing systems, gas plasma treatment equipment, and destructive and non-destructive testing technologies (including bond testers and x-ray/acoustic/optical inspection systems) for the semiconductor and printed circuit board industries.

Nordson reaches customers through a hybrid go-to-market model combining a direct sales force with third-party distributors and sales representatives, a structure typical of diversified industrial equipment makers serving both high-volume manufacturing customers and specialized medical and electronics end markets.

Headlines to Watch Out For

Semiconductor inspection demand lifts Advanced Technology Solutions order growth
Disposable hygiene and packaging automation drives Industrial Precision Solutions revenue
Medical fluid and interventional device sales expand margins through mix shift

Piotroski VR-10 (Strict) 8.0

Net Income: 555.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 3.21 > 1.0
NWC/Revenue: 20.12% < 20% (prev 19.53%; Δ 0.59% < -1%)
CFO/TA 0.13 > 3% & CFO 777.9m > Net Income 555.2m
Net Debt (1.79b) to EBITDA (947.4m): 1.89 < 3
Current Ratio: 1.82 > 1.5 & < 3
Outstanding Shares: last quarter (56.0m) vs 12m ago -1.77% < -2%
Gross Margin: 55.29% > 18% (prev 54.56%; Δ 0.73% > 0.5%)
Asset Turnover: 49.84% > 50% (prev 46.33%; Δ 3.51% > 0%)
Interest Coverage Ratio: 6.98 > 6 (EBIT TTM 799.9m / Interest Expense TTM 114.5m)

Altman Z'' 5.51

A: 0.10 (Total Current Assets 1.33b - Total Current Liabilities 728.5m) / Total Assets 5.95b
B: 0.82 (Retained Earnings 4.87b / Total Assets 5.95b)
C: 0.13 (EBIT TTM 799.9m / Avg Total Assets 5.98b)
D: 1.22 (Book Value of Equity 3.27b / Total Liabilities 2.68b)
Altman-Z'' = 5.51 = AAA

Beneish M -2.97

DSRI: 1.03 (Receivables 648.8m/589.0m, Revenue 2.98b/2.78b)
GMI: 0.99 (GM 54.56% / 55.29%)
AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68)
SGI: 1.07 (Revenue 2.98b / 2.78b)
TATA: -0.04 (NI 555.2m - CFO 777.9m) / TA 5.95b)
Beneish M = -2.97 (Cap -4..+1) = A

What is the price of NDSN shares?

As of August 24, 2026, the stock is trading at USD 332.24 with a total of 634,763 shares traded. Over the past week, the price has changed by +7.62%, over one month by +13.74%, over three months by +15.76% and over the past year by +49.08%.

Current recommended Stop Loss: 323.00 (which is 2.8% or 1.2 ATR below the current price).

Is NDSN a buy, sell or hold?

Nordson has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy NDSN.

StrongBuy: 5
Buy: 2
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the NDSN price?

Analysts Target Price	320.4	-3.6%

Nordson (NDSN) - Fundamental Data Overview as of 22 August 2026

Market Cap USD = 18.6b (18.6b USD * 1.0 USD.USD)
P/E Trailing = 33.1386
P/E Forward = 24.7525
P/S = 6.4226
P/B = 5.3868
P/EG = 1.9125
Revenue TTM = 2.98b USD
EBIT TTM = 799.9m USD
EBITDA TTM = 947.4m USD
Long Term Debt = 1.68b USD (from longTermDebt, last fiscal year)
Short Term Debt = 227.1m USD (from shortTermDebt, last quarter)
Debt = 1.90b USD (from shortLongTermDebtTotal, last quarter) + Leases 87.4m
Net Debt = 1.79b USD (calculated: Debt 1.90b - CCE 113.4m)
Enterprise Value = 20.4b USD (18.6b + Debt 1.90b - CCE 113.4m)
Interest Coverage Ratio = 6.98 (Ebit TTM 799.9m / Interest Expense TTM 114.5m)
EV/FCF = 28.05x (Enterprise Value 20.4b / FCF TTM 728.5m)
FCF Yield = 3.56% (FCF TTM 728.5m / Enterprise Value 20.4b)
FCF Margin = 24.45% (FCF TTM 728.5m / Revenue TTM 2.98b)
Net Margin = 18.63% (Net Income TTM 555.2m / Revenue TTM 2.98b)
Gross Margin = 55.29% ((Revenue TTM 2.98b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 55.49% (prev 54.54%)
Tobins Q-Ratio = 3.44 (Enterprise Value 20.4b / Total Assets 5.95b)
Interest Expense / Debt = 6.02% (Interest Expense 114.5m / Debt 1.90b)
Taxrate = 17.69% (119.3m / 674.5m)
NOPAT = 658.4m (EBIT 799.9m * (1 - 17.69%))
Current Ratio = 1.82 (Total Current Assets 1.33b / Total Current Liabilities 728.5m)
Debt / Equity = 0.58 (Debt 1.90b / totalStockholderEquity, last quarter 3.27b)
Debt / EBITDA = 1.89 (Net Debt 1.79b / EBITDA 947.4m)
Debt / FCF = 2.45 (Net Debt 1.79b / FCF TTM 728.5m)
Total Stockholder Equity = 3.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.29% (Net Income 555.2m / Total Assets 5.95b)
RoE = 17.59% (Net Income TTM 555.2m / Total Stockholder Equity 3.16b)
RoCE = 16.53% (EBIT 799.9m / Capital Employed (Equity 3.16b + L.T.Debt 1.68b))
RoIC = 12.35% (NOPAT 658.4m / Invested Capital 5.33b)
WACC = 9.17% (E(18.6b)/V(20.6b) * Re(9.60%) + D(1.90b)/V(20.6b) * Rd(6.02%) * (1-Tc(0.18)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.61 | Cagr: -1.28%
[DCF] Terminal Value 75.36% ; FCFF base≈654.3m ; Y1≈750.0m ; Y5≈1.10b
[DCF] Fair Price = 228.4 (EV 14.5b - Net Debt 1.79b = Equity 12.7b / Shares 55.7m; r=9.17% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.32 | EPS CAGR: 8.06% | SUE: 2.51 | # QB: 1
Revenue Correlation: 94.24 | Revenue CAGR: 4.34% | SUE: 2.71 | # QB: 1
EPS current Quarter (2027-01-31): EPS=2.55 | Chg30d=+0.19% | Revisions=-25% | Analysts=3
EPS current Year (2026-10-31): EPS=11.67 | Chg30d=+0.69% | Revisions=-25% | GrowthEPS=+14.0% | GrowthRev=+7.5%
EPS next Year (2027-10-31): EPS=12.57 | Chg30d=+0.23% | Revisions=-25% | GrowthEPS=+7.8% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -50% (up=0, down=3)